Table 3.

Multicovariate Cox regression models evaluating BRAFV600-mutant cfDNA percentage and RMH score with respect to OS or TTF

VariableHR95% CIP
OS, all 160 patients
 BRAFV600 cfDNA (≤2% vs. >2%)0.650.40–1.050.080
RMH score (0 or 1 vs. 2 or 3)0.400.27–0.60<0.001
OS, 98 patients without colorectal cancer
 BRAFV600 cfDNA (≤2% vs. >2%)0.620.34–1.150.130
RMH score (0 or 1 vs. 2 or 3)0.360.21–0.62<0.001
TTF, 51 patients with BRAF-mutant tumors treated with BRAF/MEK inhibitors
 BRAFV600 cfDNA (≤2% vs. >2%)0.310.14–0.680.004
RMH score (0 or 1 vs. 2 or 3)0.620.33–1.160.140